Towards the CSNK2 phosphoproteome - With lessons from the COVID-19 pandemic to revealing the secrets of CSNK2 and its promise as a therapeutic target

David W Litchfield; Laszlo Gyenis; Daniel Menyhart; Scott E Roffey

doi:10.1016/j.bbagen.2023.130441

Towards the CSNK2 phosphoproteome - With lessons from the COVID-19 pandemic to revealing the secrets of CSNK2 and its promise as a therapeutic target

Biochim Biophys Acta Gen Subj. 2023 Oct;1867(10):130441. doi: 10.1016/j.bbagen.2023.130441. Epub 2023 Aug 4.

Authors

David W Litchfield¹, Laszlo Gyenis², Daniel Menyhart², Scott E Roffey²

Affiliations

¹ Department of Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6A 5C1, Canada; Department of Oncology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6A 5C1, Canada. Electronic address: litchfi@uwo.ca.
² Department of Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6A 5C1, Canada.

PMID: 37543358
DOI: 10.1016/j.bbagen.2023.130441

Abstract

Dramatic advances in phosphoproteomics and the development of a selective chemical probe have presented new opportunities for revealing the cellular landscape of substrates for CSNK2 (formerly known as CK2 or casein kinase II). In addition to deciphering the role(s) of CSNK2 in physiology and pathophysiology, the CSNK2 phosphoproteome offers the promise of instructing the development of CSNK2-targeted therapy.

Keywords: CSNK2 (formerly CK2 or casein kinase II); CSNK2 phosphoproteome; CSNK2 viral interactions; Phosphoproteomics; SGC-CK2-1.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Casein Kinase II
Humans
Pandemics

Substances

Casein Kinase II